At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
Selpercatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized, Two-Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of Selpercatinib in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating Selpercatinib for Healthy. Completed, enrolled 46 participants across 1 site.
Detailed Summary
The main purpose of this study is to learn about how food affects selpercatinib in healthy participants. The selpercatinib will be administered in fed and fasted states. Participation could last about 7 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
CollaboratorsEli Lilly and Company
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartApr 2022
Primary CompletionJun 2022
TodayJul 2026
First PostedApr 12, 2022
Enrollment StartApr 19, 2022
Primary CompletionJun 22, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.2 years ago
Interventions
Selpercatinibdrug
Administered orally.